Prostate cancer stem cells: Research advances

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 27433-27449

  Jaworska, Dagmara ^a   Król, Wojciech ^a   Szliszka, Ewelina ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cancer stem cell; Castration resistant prostate cancer; Metastasis; Prostate cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANDROGEN RECEPTOR; ATAXIN 1; CD133 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 5; HERMES ANTIGEN; KERATIN; OSTEONECTIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER STEM CELL; CARCINOGENIC ACTIVITY; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; PROSTATE CANCER; REVIEW; STEM CELL NICHE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EID: 84947428698     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161126036     Document Type: Review

References (140)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5-29
2. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2012, 65, 87-108
3. Merseburger, A.S.; Bellmunt, J.; Jenkins, C.; Parker, C.; Fitzpatrick, J.M. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist 2013, 18, 558-567
4. Hammerer, P.; Madersbacher, S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012, 110 (Suppl. 1), 23-29
5. Clarke, N.W. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. BJU Int. 2012, 110 (Suppl. 1), 14-22
6. Sabbath, K.D.; Ball, E.D.; Larcom, P.; Davis, R.B.; Griffin, J.D. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J. Clin. Investig. 1985, 75, 746-753
7. Collins, A.T.; Maitland, N.J. Prostate cancer stem cells. Eur. J. Cancer 2006, 42, 1213-1218
8. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737
9. Sherwood, E.R.; Theyer, G.; Steiner, G.; Berg, L.A.; Kozlowski, J.M.; Lee, C. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate 1991, 18, 303-314
10. Verhagen, A.P.; Ramaekers, F.C.; Aalders, T.W.; Schaafsma, H.E.; Debruyne, F.M.; Schalken, J.A. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 1992, 52, 6182-6187
11. Bonkhoff, H. Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur. Urol. 1996, 30, 201-205
12. Taylor, R.A.; Toivanen, R.; Risbridger, G.P. Stem cells in prostate cancer: Treating the root of the problem. Endocr. Relat. Cancer 2010, 17, R273-R285
13. Nouri, M.; Ratther, E.; Stylianou, N.; Nelson, C.C.; Hollier, B.G.; Williams, E.D. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: An opportunity for intervention. Front. Oncol. 2014, 4, 1-19
14. Feitelson, M.A.; Arzumanyan, A.; Kulathinal, R.J.; Blain, S.W.; Holcombe, R.F.; Mahajna, J.; Marino, M.; Martinez-Chantar, M.L.; Nawroth, R.; Sanchez-Garcia, I.; et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin. Cancer Biol. 2015
15. Zhou, Y.; Yang, J.; Zhang, R.; Kopecek, J. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur. J. Pharm. Biopharm. 2015, 89, 107-115
16. Alberti, C. Prostate cancer: Radioresistance molecular target-related markers and foreseeable modalities of radiosensitization. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 2275-2282
17. Tuch, B.E. Stem cells-A clinical update. Aust. Fam. Physician 2006, 35, 719-721
18. D’Andrea, V.; Guarino, S.; di Matteo, F.M.; Maugeri Saccà, M.; de Maria, R. Cancer stem cells in surgery. G. Chir. 2014, 35, 257-259
19. Fulawka, L.; Donizy, P.; Halon, A. Cancer stem cells-The current status of an old concept: Literature review and clinical approaches. Biol. Res. 2014
20. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344
21. Jiang, W.; Peng, J.; Zhang, Y.; Cho, W.C.; Jin, K. The implications of cancer stem cells for cancer therapy. Int. J. Mol. Sci. 2012, 13, 16636-16657
22. Chen, X.; Zhang, J.; Zhang, Z.; Li, H.; Cheng, W.; Liu, J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum. Pathol. 2013, 44, 2373-2384
23. Economopoulou, P.; Kaklamani, V.G.; Siziopikou, K. The role of cancer stem cells in breast cancer initiation and progression: Potential cancer stem cell-directed therapies. Oncologist 2012, 17, 1394-1401
24. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488, 522-526
25. Yang, G.; Xue, F.; Chen, X. Prognostic value of different amounts of cancer stem cells in different molecular subtypes of breast cancer. Gland Surg. 2012, 1, 20-24
26. Gudadze, M.; Kankava, Q.; Mariamidze, A.; Burkadze, G. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast. Georgian Med. News 2014, 228, 81-87
27. Korski, K.; Malicka-Durczak, A.; Breborowicz, J. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Pol. J. Pathol. 2014, 65, 291-295
28. Clarke, M.F.; Fuller, M. Stem cells and cancer: Two faces of eve. Cell 2006, 124, 1111-1115
29. Pedersen, E.A.; Shiozawa, Y.; Pienta, K.J.; Taichman, R.S. The prostate cancer bone marrow niche: More than just ‘fertile soil’. Asian J. Androl. 2012, 14, 423-427
30. Shiozawa, Y.; Pedersen, E.A.; Havens, A.M.; Jung, Y.; Mishra, A.; Joseph, J.; Kim, J.K.; Patel, L.R.; Ying, C.; Ziegler, A.M.; et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Investig. 2011, 121, 1298-1312
31. Shiozawa, Y.; Eber, M.R.; Berry, J.E.; Taichman, R.S. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. BoneKEy Rep. 2015
32. Soeda, A.; Shaffrey, M.E.; Park, D.M. Cancer stem cells and glioblastoma multiforme: Pathophysiological and clinical aspects. In Advances in Cancer Stem Cells Biology; Scatena, R., Mordente, A., Giardina, B., Eds.; Springer Science & Business Media: New York, NY, USA, 2011; pp. 123-140.
33. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988
34. O’Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110
35. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951
36. Sell, S.; Leffert, H.L. Liver cancer stem cells. J. Clin. Oncol. 2008, 26, 2800-2805
37. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828
38. Yang, Z.F.; Ho, D.W.; Ng, M.N.; Lau, C.K.; Yu, W.C.; Ngai, P.; Chu, P.W.; Lam, C.T.; Poon, R.T.; Fan, S.T. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13, 153-166
39. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; de Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15, 504-514
40. Schatton, T.; Murphy, G.F.; Frank, N.Y.; Yamaura, K.; Waaga-Gasser, A.M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L.M.; Weishaupt, C.; et al. Identification of cells initiating human melanomas. Nature 2008, 451, 345-349
41. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320
42. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030-1037
43. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715
44. Corominas-Faja, B.; Cufí, S.; Oliveras-Ferraros, C.; Cuyàs, E.; López-Bonet, E.; Lupu, R.; Alarcón, T.; Vellon, L.; Iglesias, J.M.; Leis, O.; et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle 2013, 12, 3109-3124
45. Parimi, V.; Goyal, R.; Poropatich, K.; Yang, X.J. Neuroendocrine differentiation of prostate cancer: A review. Am. J. Clin. Exp. Urol. 2014, 2, 273-285
46. Amorino, G.P.; Parsons, S.J. Neuroendocrine cells in prostate cancer. Crit. Rev. Eukaryot. Gene Expr. 2004, 14, 287-300
47. De Marzo, A.M.; Meeker, A.K.; Epstein, J.I.; Coffey, D.S. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 1998, 153, 911-919
48. Brawer, M.K.; Peehl, D.M.; Stamey, T.A.; Bostwick, D.G. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985, 45, 3663-3667
49. Alam, T.N.; O’Hare, M.J.; Laczkó, I.; Freeman, A.; Al-Beidh, F.; Masters, J.R.; Hudson, D.L. Differential expression of CD44 during human prostate epithelial cell differentiation. J. Histochem. Cytochem. 2004, 52, 1083-1090
50. Bello-DeOcampo, D.; Kleinman, H.K.; Deocampo, N.D.;Webber, M.M. Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 2001, 46, 142-153
51. Knox, J.D.; Cress, A.E.; Clark, V.; Manriquez, L.; Affinito, K.S.; Dalkin, B.L.; Nagle, R.B. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am. J. Pathol. 1994, 145, 167-174
52. Signoretti, S.; Waltregny, D.; Dilks, J.; Isaac, B.; Lin, D.; Garraway, L.; Yang, A.; Montironi, R.; McKeon, F.; Loda, M. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000, 157, 1769-1775
53. Wang, Y.; Hayward, S.; Cao, M.; Thayer, K.; Cunha, G. Cell differentiation lineage in the prostate. Differentiation 2001, 68, 270-279
54. Hudson, D.L.; O’Hare, M.; Watt, F.M.; Masters, J.R. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells. Lab. Investig. 2000, 80, 1243-1250
55. Xue, Y.; Smedts, F.; Debruyne, F.M.; de la Rosette, J.J.; Schalken, J.A. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 1998, 34, 292-301
56. Liu, A.Y.; Peehl, D.M. Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res. 2001, 305, 389-397
57. Petkova, N.; Hennenlotter, J.; Sobiesiak, M.; Todenhöfer, T.; Scharpf, M.; Stenzl, A.; Bühring, H.J.; Schwentner, C. Surface CD24 distinguishes between low differentiated and transit-amplifying cells in the basal layer of human prostate. Prostate 2013, 73, 1576-1590
58. Lee, D.K.; Liu, Y.; Liao, L.; Wang, F.; Xu, J. The prostate basal cell (BC) heterogeneity and the p63-positive BC differentiation spectrum in mice. Int. J. Biol. Sci. 2014, 10, 1007-1017
59. Goldstein, A.S.; Lawson, D.A.; Cheng, D.; Sun, W.; Garraway, I.P.; Witte, O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. USA 2008, 105, 20882-20887
60. Trerotola, M.; Rathore, S.; Goel, H.L.; Li, J.; Alberti, S.; Piantelli, M.; Adams, D.; Jiang, Z.; Languino, L.R. CD133, Trop-2 and β2 β 1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am. J. Transl. Res. 2010, 2, 135-144
61. Richardson, G.D.; Robson, C.N.; Lang, S.H.; Neal, D.E.; Maitland, N.J.; Collins, A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004, 117, 3539-3545
62. Kania, G.; Corbeil, D.; Fuchs, J.; Tarasov, K.V.; Blyszczuk, P.; Huttner, W.B.; Boheler, K.R.; Wobus, A.M. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells 2005, 23, 791-804
63. Sykes, A.M.; Huttner, W.B. Prominin-1 (CD133) and the cell biology of neural progenitors and their progeny. Adv. Exp. Med. Biol. 2013, 777, 89-98
64. Missol-Kolka, E.; Karbanová, J.; Janich, P.; Haase, M.; Fargeas, C.A.; Huttner, W.B.; Corbeil, D. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate 2011, 71, 254-267
65. Rycaj, K.; Tang, D.G. Cell-of-origin of cancer versus cancer stem cells: Assays and interpretations. Cancer Res. 2015
66. Sharpe, B.; Beresford, M.; Bowen, R.; Mitchard, J.; Chalmers, A.D. Searching for prostate cancer stem cells: Markers and methods. Stem Cell Rev. 2013, 9, 721-730
67. Tu, S.M.; Bilen, M.A.; Tannir, N.M. The scientific method: Pillar and pitfall of cancer research. Cancer Med. 2014, 3, 1035-1037
68. Signoretti, S.; Loda, M. Prostate stem cells: From development to cancer. Semin. Cancer Biol. 2007, 17, 219-224
69. Hurt, E.M.; Kawasaki, B.T.; Klarmann, G.J.; Thomas, S.B.; Farrar,W.L. CD44+CD24_ prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98, 756-765
70. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J.G.; Chandra, D.; Zhou, J.; Claypool, K.; et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25, 1696-1708
71. Jiao, J.; Hindoyan, A.; Wang, S.; Tran, L.M.; Goldstein, A.S.; Lawson, D.; Chen, D.; Li, Y.; Guo, C.; Zhang, B.; et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS ONE 2012, 7, e42564
72. Lang, S.H.; Frame, F.M.; Collins, A.T. Prostate cancer stem cells. J. Pathol. 2009, 217, 299-306
73. Baccelli, I.; Trumpp, A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 2012, 198, 281-293
74. Zenzmaier, C.; Untergasser, G.; Berger, P. Aging of the prostate epithelial stem/progenitor cell. Exp. Gerontol. 2008, 43, 981-985
75. Gu, G.; Yuan, J.; Wills, M.; Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007, 67, 4807-4815
76. Maitland, N.J.; Bryce, S.D.; Stower, M.J.; Collins, A.T. Prostate cancer stem cells: A target for new therapies. Ernst Schering Found. Symp. Proc. 2006, 5, 155-179
77. Maitland, N.J.; Collins, A.T. Prostate cancer stem cells: A new target for therapy. J. Clin. Oncol. 2008, 26, 2862-2870
78. Dunning, N.L.; Laversin, S.A.; Miles, A.K.; Rees, R.C. Immunotherapy of prostate cancer: Should we be targeting stem cells and EMT? Cancer Immunol. Immunother. 2011, 60, 1181-1193
79. Liu, T.; Xu, F.; Du, X.; Lai, D.; Zhao, Y.; Huang, Q.; Jiang, L.; Huang, W.; Cheng, W.; Liu, Z. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol. Cell. Biochem. 2010, 340, 265-273
80. Mimeault, M.; Johansson, S.L.; Vankatraman, G.; Moore, E.; Henichart, J.P.; Depreux, P.; Lin, M.F.; Batra, S.K. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol. Cancer Ther. 2007, 6, 967-978
81. Mimeault, M.; Johansson, S.L.; Henichart, J.P.; Depreux, P.; Batra, S.K. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther. 2010, 9, 617-630
82. Rossi, D.J.; Weissman, I.L. Pten, tumorigenesis, and stem cell self-renewal. Cell 2006, 125, 229-231
83. Hill, R.; Wu, H. Pten, stem cells, and cancer stem cells. J. Biol. Chem. 2009, 284, 11755-11759
84. Korsten, H.; Ziel-vander Made, A.; Ma, X.; vander Kwast, T.; Trapman, J. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS ONE 2009, 4, e5662
85. Wang, X.; Kruithof-de Julio, M.; Economides, K.D.; Walker, D.; Yu, H.; Halili, M.V.; Hu, Y.P.; Price, S.M.; Abate-Shen, C.; Shen, M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461, 495-500
86. Wang, Z.A.; Toivanen, R.; Bergren, S.K.; Chambon, P.; Shen, M.M. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep. 2014, 8, 1339-1346
87. Azmi, A.S.; Sarkar, F.H. Prostate cancer stem cells: Molecular characterization for targeted therapy. Asian J. Androl. 2012, 14, 659-660
88. Dawood, S.; Austin, L.; Cristofanilli, M. Cancer stem cells: Implications for cancer therapy. Oncology (Williston Park) 2014, 28, 1101-1107, 1110
89. Sharifi, N.; Kawasaki, B.T.; Hurt, E.M.; Farrar, W.L. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol. Ther. 2006, 5, 901-906
90. Williams, K.; Motiani, K.; Giridhar, P.V.; Kasper, S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp. Biol. Med. (Maywood) 2013, 238, 324-338
91. Yu, C.; Shiozawa, Y.; Taichman, R.S.; McCauley, L.K.; Pienta, K.; Keller, E. Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit. Rev. Eukaryot. Gene Expr. 2012, 22, 131-148
92. Mateo, F.; Meca-Cortés, O.; Celià-Terrassa, T.; Fernández, Y.; Abasolo, I.; Sánchez-Cid, L.; Bermudo, R.; Sagasta, A.; Rodríguez-Carunchio, L.; Pons, M.; et al. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol. Cancer 2014, 13
93. Mathieu, J.; Zhang, Z.; Zhou, W.; Wang, A.J.; Heddleston, J.M.; Pinna, C.M.; Hubaud, A.; Stadler, B.; Choi, M.; Bar, M.; et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011, 71, 4640-4652
94. Ravenna, L.; Principessa, L.; Verdina, A.; Salvatori, L.; Russo, M.A.; Petrangeli, E. Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression. PLoS ONE 2014, 9, e96250
95. Dai, Y.; Bae, K.; Siemann, D.W. Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 521-528
96. Ma, Y.; Liang, D.; Liu, J.; Axcrona, K.; Kvalheim, G.; Stokke, T.; Nesland, J.M.; Suo, Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS ONE 2011, 6, e29170
97. Weckermann, D.; Müller, P.; Wawroschek, F.; Harzmann, R.; Riethmüller, G.; Schlimok, G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: Detection and prognostic value. J. Urol. 2001, 166, 699-703
98. Rahim, F.; Hajizamani, S.; Mortaz, E.; Ahmadzadeh, A.; Shahjahani, M.; Shahrabi, S.; Saki, N. Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res. 2014, 2014
99. Luo, J.; Ok Lee, S.; Liang, L.; Huang, C.K.; Li, L.; Wen, S.; Chang, C. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2014, 33, 2768-2778
100. Mulholland, D.J.; Xin, L.; Morim, A.; Lawson, D.; Witte, O.; Wu, H. LinβSca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009, 69, 8555-8562
101. Corbeil, D.; Röper, K.; Fargeas, C.A.; Joester, A.; Huttner, W.B. Prominin: A story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2, 82-91
102. Yin, A.H.; Miraglia, S.; Zanjani, E.D.; Almeida-Porada, G.; Ogawa, M.; Leary, A.G.; Olweus, J.; Kearney, J.; Buck, D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90, 5002-5012
103. Bauer, N.; Fonseca, A.V.; Florek, M.; Freund, D.; Jászai, J.; Bornhäuser, M.; Fargeas, C.A.; Corbeil, D. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008, 188, 127-138
104. Vander Griend, D.J.; Karthaus, W.L.; Dalrymple, S.; Meeker, A.; DeMarzo, A.M.; Isaacs, J.T. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008, 68, 9703-9711
105. Rentala, S.; Yalavarthy, P.D.; Mangamoori, L.N. β1 and β 1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J. Androl. 2010, 12, 548-555
106. Liu, S.; Cheng, C. Alternative RNA splicing and cancer. Wiley Interdiscip. Rev. RNA 2013, 4, 547-566
107. Iborra, S.; Hirschfeld, M.; Jaeger, M.; Zur Hausen, A.; Braicu, I.; Sehouli, J.; Gitsch, G.; Stickeler, E. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact. Int. J. Gynecol. Cancer 2013, 23, 990-996
108. Jordan, A.R.; Racine, R.R.; Hennig, M.J.; Lokeshwar, V.B. The role of CD44 in disease pathophysiology and targeted treatment. Front. Immunol. 2015
109. Shirure, V.S.; Liu, T.; Delgadillo, L.F.; Cuckler, C.M.; Tees, D.F.; Benencia, F.; Goetz, D.J.; Burdick, M.M. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions. Am. J. Physiol. Cell Physiol. 2015, 308, C68-C78
110. Salmi, M.; Karikoski, M.; Elima, K.; Rantakari, P.; Jalkanen, S. CD44 binds to macrophage mannose receptor on lymphatic endothelium and supports lymphocyte migration via afferent lymphatics. Circ. Res. 2013, 112, 1577-1582
111. Klarmann, G.J.; Hurt, E.M.; Mathews, L.A.; Zhang, X.; Duhagon, M.A.; Mistree, T.; Thomas, S.B.; Farrar, W.L. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 2009, 26, 433-446
112. Rybak, A.P.; He, L.; Kapoor, A.; Cutz, J.C.; Tang, D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim. Biophys. Acta 2011, 1813, 683-694
113. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.; Lonigro, R.J.; Brenner, J.C.; et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239-243
114. Vis, A.N.; Schröder, F.H. Key targets of hormonal treatment of prostate cancer. Part 1: The androgen receptor and steroidogenic pathways. BJU Int. 2009, 104, 438-448
115. Semenas, J.; Allegrucci, C.; Boorjian, S.A.; Mongan, N.P.; Persson, J.L. Overcoming drug resistance and treating advanced prostate cancer. Curr. Drug Targets 2012, 13, 1308-1323
116. Ni, J.; Cozzi, P.; Hao, J.; Duan, W.; Graham, P.; Kearsley, J.; Li, Y. Cancer stem cells in prostate cancer chemoresistance. Curr. Cancer Drug Targets 2014, 14, 225-240
117. Bishop, J.L.; Davies, A.; Ketola, K.; Zoubeidi, A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr. Relat. Cancer 2015, 22, R165-R182
118. Zhang, L.; Jiao, M.; Li, L.; Wu, D.; Wu, K.; Li, X.; Zhu, G.; Dang, Q.; Wang, X.; Hsieh, J.T.; et al. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 2012, 138, 675-686
119. Singh, P.; Uzgare, A.; Litvinov, I.; Denmeade, S.R.; Isaacs, J.T. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer 2006, 13, 653-666
120. Njar, V.C.; Brodie, A.M. Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem. 2015, 58, 2077-2087
121. Adeniji, A.O.; Chen, M.; Penning, T.M. AKR1C3 as a target in castrate resistant prostate cancer. J. Steroid Biochem. Mol. Biol. 2013, 137, 136-149
122. Shiota, M.; Yokomizo, A.; Fujimoto, N.; Naito, S. Androgen receptor cofactors in prostate cancer: Potential therapeutic targets of castration-resistant prostate cancer. Curr. Cancer Drug Targets 2011, 11, 870-881
123. De Leon, J.T.; Iwai, A.; Feau, C.; Garcia, Y.; Balsiger, H.A.; Storer, C.L.; Suro, R.M.; Garza, K.M.; Lee, S.; Kim, Y.S.; et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11878-11883
124. Kregel, S.; Kiriluk, K.J.; Rosen, A.M.; Cai, Y.; Reyes, E.E.; Otto, K.B.; Tom, W.; Paner, G.P.; Szmulewitz, R.Z.; Vander Griend, D.J. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS ONE 2013, 8, e53701
125. Li, Y.; Hwang, T.H.; Oseth, L.A.; Hauge, A.; Vessella, R.L.; Schmechel, S.C.; Hirsch, B.; Beckman, K.B.; Silverstein, K.A.; Dehm, S.M. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012, 31, 4759-4767
126. Zhang, X.; Morrissey, C.; Sun, S.; Ketchandji, M.; Nelson, P.S.; True, L.D.; Vakar-Lopez, F.; Vessella, R.L.; Plymate, S.R. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011, 6, e27970
127. Lu, J.; Van der Steen, T.; Tindall, D.J. Are androgen receptor variants a substitute for the full-length receptor? Nat. Rev. Urol. 2015, 12, 137-144
128. Lu, C.; Luo, J. Decoding the androgen receptor splice variants. Transl. Androl. Urol. 2013, 2, 178-186
129. Sun, Y.; Wang, B.E.; Leong, K.G.; Yue, P.; Li, L.; Jhunjhunwala, S.; Chen, D.; Seo, K.; Modrusan, Z.; Gao, W.Q.; et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res. 2012, 72, 527-536
130. Kong, D.; Sethi, S.; Li, Y.; Chen, W.; Sakr, W.A.; Heath, E.; Sarkar, F.H. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate 2015, 75, 161-174
131. Hirsch, H.A.; Iliopoulos, D.; Struhl, K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. USA 2013, 110, 972-977
132. Iliopoulos, D.; Hirsch, H.A.; Wang, G.; Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108, 1397-1402
133. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71, 3196-3201
134. Mayer, M.J.; Klotz, L.H.; Venkateswaran, V. Metformin and prostate cancer stem cells: A novel therapeutic target. Prostate Cancer Prostatic Dis. 2015
135. Vallianou, N.G.; Evangelopoulos, A.; Kazazis, C. Metformin and cancer. Rev. Diabet. Stud. 2013, 10, 228-235
136. Bilen, M.A.; Lin, S.H.; Tang, D.G.; Parikh, K.; Lee, M.H.; Yeung, S.C.; Tu, S.M. Maintenance therapy containing Metformin and/or Zyflamend for advanced prostate cancer: A case series. Case Rep. Oncol. Med. 2015
137. Li, Y.; Wicha, M.S.; Schwartz, S.J.; Sun, D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem. 2011, 22, 799-806
138. Scarpa, E.S.; Ninfali, P. Phytochemicals as innovative therapeutic tools against cancer stem cells. Int. J. Mol. Sci. 2015, 16, 15727-15742
139. Teiten, M.H.; Gaigneaux, A.; Chateauvieux, S.; Billing, A.M.; Planchon, S.; Fack, F.; Renaut, J.; Mack, F.; Muller, C.P.; Dicato, M.; et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS 2012, 16, 289-300
140. Botchkina, G.I.; Zuniga, E.S.; Rowehl, R.H.; Park, R.; Bhalla, R.; Bialkowska, A.B.; Johnson, F.; Golub, L.M.; Zhang, Y.; Ojima, I.; et al. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS ONE 2013, 8, e69884